← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV18행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
adebrelimab and chemotherapy (adebrelimab and chemotherapy)
Jiangsu Hansoh Pharmaceutical Co.,…·Efficacy and Safety of Neoadjuvant…
54 trials
Overview
Program
adebrelimab and chemotherapy
Overview
Company
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Overview
Modality
ANTIBODY
Overview
Target
Efficacy and Safety of Neoadjuvant Immun
Overview
Indication
Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Biomarker
PD-L1 antibody), and bevacizumab in refractory non-microsatellite instability-high
PK/PD
Animal (cat.)
Unknown
PK/PD
Experiment
PD
Toxicology
Animal (cat.)
Unknown
Toxicology
Major finding
pneumonitis was 25% (17/67) and 6% (4/67), respectively
Clinical
Safety signal
pneumonitis was 25% (17/67) and 6% (4/67), respectively
Clinical
Program phase
PHASE_2